2023 is witnessing a surge in the M&A deals. Are all deals based on sound business strategies?
April 18, 2023 ⚊ 1 Min read ⚊ Views 73 ⚊ BLOGWhile the current geopolitical and economic conditions are not ideal, the increasing M&A deals in 2023 show a promising sign in the market. More deals were signed in January 2023 than in the entire span of the last three years. Companies like Pfizer, AstraZeneca, Ipsen, and Chiesi contributed to a total of about $47B in biopharma deal announcements in first quarter of 2023.
Tags: healthcare